+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Factors associated with methotrexate dosing and therapeutic decisions in veterans with rheumatoid arthritis



Factors associated with methotrexate dosing and therapeutic decisions in veterans with rheumatoid arthritis



Clinical Rheumatology 33(1): 21-30



The purpose of this study is to explore patient factors associated with differences in methotrexate (MTX) dosing and to compare patient factors and MTX-dosing patterns between those who remained on MTX monotherapy and those who were switched or had additional therapy. A retrospective cohort of 7,017 patients with newly diagnosed rheumatoid arthritis (RA) was identified in the United States Department of Veterans Affairs administrative databases between 1 October 1999 and 30 September 2009. Regression analyses were used to study the association of MTX start and maximum dose attained with various patient characteristics and compare differences between groups who had therapeutic change (having switched to or added another anti-rheumatic agent or having steroids increased by 2.5 mg of prednisone or equivalent) with those remaining on MTX monotherapy. Abnormal serum creatinine (>1.5 mg/dL) was associated lower start and peak MTX doses (p < 0.01). Older RA patients were less likely to attain peak MTX dose of 15 mg or more (p < 0.01). Males and patients 75 and older (compared with <45) had lower risk of therapeutic change (hazard ratio, [HR] 0.80, 95 % confidence interval [CI] 0.72-0.90, and HR 0.42, 95% CI 0.42-0.36-0.50, respectively). Patients who attained higher peak MTX dose had lower risk of therapeutic change compared with those dosed at less than 15 mg/week (HR 0.85, 95% CI 0.77-0.92 for 15 to <20 and HR 0.79, 95% CI 0.72-0.86 for 20 or more). Injectable MTX use conferred lower risk of therapeutic change (HR 0.64, 95% CI 0.52-0.78). Two thirds did not attain a maximum MTX dose of 20 mg/week or more before therapeutic change occurred. Older age and renal insufficiency were barriers to the use of higher MTX maximum dosages. Use of injectable MTX and higher maximum MTX dose were independently associated with higher likelihood to remain on MTX monotherapy. Further studies are needed to explore targeted interventions that may optimize MTX dosing to improve success rates of MTX monotherapy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053193691

Download citation: RISBibTeXText

PMID: 23934386

DOI: 10.1007/s10067-013-2353-9


Related references

Factors associated with methotrexate dosing and therapeutic decisions in veterans with rheumatoid arthritis. Journal of Allergy and Clinical Immunology 131(2): AB66, 2013

Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis. Journal of Rheumatology 40(6): 809-817, 2013

Patients with Rheumatoid Arthritis in Remission While Receiving Etanercept Plus Methotrexate Therapy May Require Adjustment of Dosing Regimen When Switched to Methotrexate Monotherapy. Journal of Rheumatology 44(2): 259, 2017

Factors influencing therapeutic effect of methotrexate treatment in rheumatoid arthritis patients. Reumatologia 37(1): 40-52, 1999

Subtherapeutic dosing of methotrexate in rheumatoid arthritis trials. Journal of the American Osteopathic Association 104(1): 7-8, 2004

Post-dosing reactions to methotrexate in patients with rheumatoid arthritis. Arthritis & Rheumatism 36(9 Suppl. ): S80, 1993

Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. British Journal of Rheumatology 36(1): 86-90, 1997

Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome. Pharmacogenomics 17(15): 1649-1674, 2016

Therapeutic efficacy of cationic liposomes carrying methotrexate (endoMTX) is superior to free methotrexate in rheumatoid arthritis in vivo. 2007

Methotrexate Reduces Incidence of Vascular Diseases in Veterans With Psoriasis or Rheumatoid Arthritis. Yearbook of Dermatology and Dermatologic Surgery 2006: 86-87, 2006

Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. Journal of the American Academy of Dermatology 52(2): 262-267, 2005

Making rational treatment decisions in rheumatoid arthritis when methotrexate fails. New England Journal of Medicine 369(4): 384-385, 2013

THU0235Prevention of Development of Rheumatoid Arthritis (RA) in Patients with Undifferentiated Arthritis (UA) by Very Early Therapeutic Intervention of Methotrexate (MTX). Annals of the Rheumatic Diseases 72(Suppl 3): A244.2-A244, 2013

Disposition and clinical efficacy of methotrexate in patients with rheumatoid arthritis following weekly, low, intramuscular dosing: A pilot study. Current Therapeutic Research 58(7): 434-445, 1997

The efficacy of etidronate risedronate and methotrexate in immunosuppressive and therapeutic dosing regimens in adjuvant arthritis. Arthritis & Rheumatism 34(9 Suppl.): S158, 1991